Moreover, the expression levels of SLC7A2 exhibit potential as a key prognostic biomarker for HNSCC, offering a new genetic target for the treatment of LNM in this cancer type. This evidence concerns the gene SLC7A2 and head and neck squamous cell carcinoma.